Slide 1: Revolutionizing Women's Health Through Ground-Breaking Technology
Revolutionizing Women's Health Through Ground-Breaking Technology July 2025 TSXV: ZCT OTCQB: ZCTFF FSE: 9L2
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements based on expectations, forecasts, and assumptions about future events or performance. These statements can be identified by terms such as “will,” “may,” “estimate,” “expect,” “plan,” “project,” “intend,” “anticipate,” o
Slide 3: ZCT Overview
ZCT OVERVIEW FemTech company developing the first AI-enabled intravaginal therapeutic device for treating vulvovaginal candidiasis (VVC), commonly known as yeast infections. The technology combines blue light therapy, targeted drug delivery, and wireless diagnostics for real time data transmission t
Slide 4: Investment Highlights
INVESTMENT HIGHLIGHTS Global antifungal SMART device – Blue FDA De Novo Opportunity to leverage Major U.S. pharma market – $15.6B + light therapy + gel + classification underway both B2B and B2C players in negotiations women’s health device AI diagnostics + pursuing fast-track models for final devic
Slide 5: The VVC Landscape
THE VVC LANDSCAPE 100-200M Recurrent (4+) VVC cases each year In Billion USD 75% VVC Treatment of women will have Market VVC at least once ~ US$2.04B FemTech Age 24-34 Market Highest prevalence and growing ~ US$115B 5 TSXV: ZCT | OTCQB: ZCTFF | FSE: 9L2
Slide 6: The Problem
THE PROBLEM Until recently, the root cause of VVC was poorly understood and inadequately addressed by existing medication: 1) Vaginal Ovules 2) Oral Drugs 3) Creams Leading to therapeutic failures... Microbial Resistence Lack of Drug Efficacy Host Susceptibilities REDUCTION IN THE ALTERATION IN THE
Slide 7: The Technology
THE TECHNOLOGY Designed to reduce side effects, frequent doctor visits, and perscriptions. A non-drug blue light therapy in a SMART vaginal diagnostic device. Offering precise and personalized treatment, with individualized light frequency targeting, to produce 99.999% fungal eradication in only 3 h
Slide 8: The Solution
THE SOLUTION ZC-01 DEVICE THERAPEUTIC BLUE LIGHT AT PRECISE WAVELENGTH AND INTENSITY GEL-BASED CLOTRIMAZOLE DELIVERY SYSTEM ARTIFICIAL INTELLIGENCE WI-FI AND VOIP CONNECTIVITY TEMPERATURE AND PH SENSORS DISCREET AND PATIENT-CENTRIC DESIGN 8 TSXV: ZCT | OTCQB: ZCTFF | FSE: 9L2
Slide 9: Upcoming Milestones
UPCOMING MILESTONES Q1 Q2 2025 Q4 2026 Q3 2026 2027 9 TSXV: ZCT | OTCQB: ZCTFF | FSE: 9L2
Slide 10: Thank You!
OTCQB: ZCTFF TSXV: ZCT FSE: 9L2 THANK YOU! investors@zero-candida.com +1 (647) 874 3767 zero-candida.com